Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAYMOND TURNER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1801977939
CMS profile
472061
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$67,139.49

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $52,173.98 49
Eisai Inc. $9,470.00 3
Eli Lilly and Company $5,415.51 6
F. Hoffmann-La Roche AG $80.00 1

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAYMOND TURNER

NPI 1801977939 · CMS profile ID 472061

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801977939?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAYMOND TURNER, NPI 1801977939, CMS profile ID 472061. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801977939?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RAYMOND TURNER, NPI 1801977939, CMS profile ID 472061. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801977939?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RAYMOND TURNER, NPI 1801977939, CMS profile ID 472061, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1801977939?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $67,139.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $950.0004/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186901122 CMS
Lilly USA, LLC $104.5804/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186875659 CMS
Lilly USA, LLC $1,575.0004/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186911586 CMS
Lilly USA, LLC $2,500.0004/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186936612 CMS
Lilly USA, LLC $113.5704/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186880465 CMS
Lilly USA, LLC $1,250.0002/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186860433 CMS
F. Hoffmann-La Roche AG $80.0002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211572618 CMS
Lilly USA, LLC $1,250.0001/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186850269 CMS
Lilly USA, LLC $1,250.0001/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186936610 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,212.67 19
PY2020 $7,806.00 4
PY2021 $159.45 13
PY2022 $6,992.53 6
PY2023 $10,282.87 8
PY2024 $55,631.51 66
PY2025 $67,139.49 59

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,354,651.49 89
PY2024 Recipient $181,340.00 2
PY2024 Principal investigator $2,978,122.35 44
PY2023 Recipient $618.00 2
PY2023 Principal investigator $4,805,249.79 72
PY2022 Recipient $93,798.00 3
PY2022 Principal investigator $1,633,499.02 29
PY2021 Principal investigator $1,780,817.80 45
PY2020 Recipient $5,019.67 3
PY2020 Principal investigator $1,000,431.00 43
PY2019 Principal investigator $1,913,977.92 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

89 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $300.00 12/31/2025 Non-covered Recipient Entity
RE COGNITION HEALTH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer s Disease No dispute reported 06/30/2026 1202534723
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 12/22/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383844
Principal investigator 1 Eisai Inc. $1,873.80 12/15/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558836
Principal investigator 1 Janssen Research & Development, LLC $1,170.00 12/15/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383733
Principal investigator 1 Janssen Research & Development, LLC $520.00 12/15/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383740
Principal investigator 1 Janssen Research & Development, LLC $1,040.00 12/15/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383880
Principal investigator 1 Eisai Inc. $7,600.00 12/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558844
Principal investigator 1 Eisai Inc. $10,225.00 12/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558860
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,350.10 11/21/2025 Non-covered Recipient Entity
Georgetown University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235997129
Principal investigator 1 Eisai Inc. $3,747.60 11/17/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558838
Principal investigator 1 GlaxoSmithKline, LLC. $27,967.48 11/12/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192160700
Principal investigator 1 Eisai Inc. $8,815.00 11/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558846
Principal investigator 1 Eisai Inc. $7,260.00 11/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558852
Principal investigator 1 Eisai Inc. $3,800.00 11/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558856
Principal investigator 1 Janssen Research & Development, LLC $2,798.00 10/31/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383904
Principal investigator 1 Janssen Research & Development, LLC $6,895.00 10/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383662
Principal investigator 1 Eisai Inc. $16,944.00 10/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558840
Principal investigator 1 GlaxoSmithKline, LLC. $20,814.33 10/21/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192162567
Principal investigator 1 Eisai Inc. $3,261.60 10/20/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558834
Principal investigator 1 Genentech, Inc. $11,500.00 10/09/2025 Non-covered Recipient Entity
RE COGNITION HEALTH CORP
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640729
Principal investigator 1 Eisai Inc. $5,820.00 10/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558842
Principal investigator 1 Eisai Inc. $1,160.00 10/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558848
Principal investigator 1 Eisai Inc. $13,335.00 10/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558850
Principal investigator 1 Eisai Inc. $86,180.00 10/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558854
Principal investigator 1 Eisai Inc. $30,460.00 10/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558858
Principal investigator 1 Eisai Inc. $7,600.00 10/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558862
Principal investigator 1 Janssen Research & Development, LLC $1,029.00 09/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383748
Principal investigator 1 GlaxoSmithKline, LLC. $13,635.12 09/16/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192160708
Principal investigator 1 Eisai Inc. $1,800.00 09/15/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558824
Principal investigator 1 Eisai Inc. $2,810.70 09/15/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558832
Principal investigator 1 Janssen Research & Development, LLC $10,835.00 09/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383777
Principal investigator 1 Eisai Inc. $48,840.00 09/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558870
Principal investigator 1 Eisai Inc. $1,075.00 09/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558884
Principal investigator 1 Eisai Inc. $11,400.00 09/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558890
Principal investigator 1 Janssen Research & Development, LLC $24,080.00 08/22/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383829
Principal investigator 1 Janssen Research & Development, LLC $8,990.00 08/22/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383925
Principal investigator 1 Janssen Research & Development, LLC $1,650.00 08/22/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383943
Principal investigator 1 GlaxoSmithKline, LLC. $29,829.44 08/13/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192162557
Principal investigator 1 Eisai Inc. $2,810.70 08/11/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558822
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 08/11/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383783
Principal investigator 1 Eisai Inc. $12,980.00 08/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558894
Principal investigator 1 Eisai Inc. $1,840.00 07/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558826
Principal investigator 1 Eisai Inc. $2,810.70 07/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558828
Principal investigator 1 GlaxoSmithKline, LLC. $20,429.19 07/21/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192160704
Principal investigator 1 Sage Therapeutics, LLC $47,742.50 07/18/2025 Non-covered Recipient Entity
COGNITION HEALTH CORPORATION
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 1206580581
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,374.42 07/14/2025 Non-covered Recipient Entity
Georgetown University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235997131
Principal investigator 1 Eisai Inc. $1,800.00 07/07/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558820
Principal investigator 1 Eisai Inc. $1,873.80 07/07/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558830
Principal investigator 1 Janssen Research & Development, LLC $1,700.00 07/07/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383935
Principal investigator 1 Eisai Inc. $3,800.00 07/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558866
Principal investigator 1 Eisai Inc. $2,150.00 07/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558868
Principal investigator 1 Eisai Inc. $49,770.00 07/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558874
Principal investigator 1 Eisai Inc. $150.00 07/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558886
Principal investigator 1 Eisai Inc. $5,590.00 07/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558900
Principal investigator 1 GlaxoSmithKline, LLC. $14,021.22 06/23/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192160695
Principal investigator 1 Janssen Research & Development, LLC $3,350.00 06/12/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383839
Principal investigator 1 Eisai Inc. $640.00 06/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558864
Principal investigator 1 Eisai Inc. $19,400.00 06/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558898
Principal investigator 1 Eli Lilly and Company $31.08 05/16/2025 Non-covered Recipient Entity
RE COGNITION HEALTH CORPORATION
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187889200
Principal investigator 1 GlaxoSmithKline, LLC. $47,854.85 05/15/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192160692
Principal investigator 1 Janssen Research & Development, LLC $3,300.00 05/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383601
Principal investigator 1 Biogen, Inc. $77,101.00 05/07/2025 Non-covered Recipient Entity
Georgetown University-Department Of Neuroscience
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1236946930
Principal investigator 1 GlaxoSmithKline, LLC. $15,381.26 04/09/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192162554
Principal investigator 1 Janssen Research & Development, LLC $1,742.00 04/07/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383621
Principal investigator 1 Eisai Inc. $6,345.00 04/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558876
Principal investigator 1 Eisai Inc. $6,185.00 04/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558896
Principal investigator 1 Eli Lilly and Company $187.50 03/25/2025 Non-covered Recipient Entity
PRES AND DIR GEORGETOWN COLLEGE FOR GRGTWN UNIV
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187890036
Principal investigator 1 GlaxoSmithKline, LLC. $27,728.42 03/21/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192160713
Principal investigator 1 Eisai Inc. $7,495.20 03/18/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558818
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $261,228.00 03/12/2025 Non-covered Recipient Entity
Re Cognition Health
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235994361
Principal investigator 1 Eisai Inc. $46,800.00 03/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558880
Principal investigator 1 Eisai Inc. $8,070.00 03/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558882
Principal investigator 1 Eisai Inc. $1,280.00 03/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558892
Principal investigator 1 GlaxoSmithKline, LLC. $47,616.45 02/24/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192162562
Principal investigator 1 Eli Lilly and Company $2,525.00 02/11/2025 Non-covered Recipient Entity
PRES AND DIR GEORGETOWN COLLEGE FOR GRGTWN UNIV
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187889578
Principal investigator 1 Janssen Research & Development, LLC $5,276.00 02/10/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383608
Principal investigator 1 Eisai Inc. $6,000.00 02/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558872
Principal investigator 1 GlaxoSmithKline, LLC. $30,481.63 01/28/2025 Non-covered Recipient Entity
COGNITION HEALTH CORP
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192162571
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,514.25 01/27/2025 Non-covered Recipient Entity
Re Cognition Health
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235994359
Principal investigator 1 Eli Lilly and Company $4,106.93 01/27/2025 Non-covered Recipient Entity
RE COGNITION HEALTH CORPORATION
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887840
Principal investigator 1 Eli Lilly and Company $18,125.72 01/27/2025 Non-covered Recipient Entity
RE COGNITION HEALTH CORPORATION
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187890232
Principal investigator 1 Eisai Inc. $4,684.50 01/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558816
Principal investigator 1 Janssen Research & Development, LLC $736.00 01/10/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175383652
Principal investigator 1 Eli Lilly and Company $502,746.00 01/07/2025 Non-covered Recipient Entity
RE COGNITION HEALTH CORPORATION
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187888752
Principal investigator 1 Eli Lilly and Company $362,235.00 01/07/2025 Non-covered Recipient Entity
RE COGNITION HEALTH CORPORATION
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187889932
Principal investigator 1 Eli Lilly and Company $200,226.00 01/07/2025 Non-covered Recipient Entity
RE COGNITION HEALTH CORPORATION
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187890228
Principal investigator 1 UCB SA $8,782.00 01/07/2025 Non-covered Recipient Entity
RE:COGNITION HEALTH CORPORATION
A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1246657766
Principal investigator 1 Eisai Inc. $1,885.00 01/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558878
Principal investigator 1 Eisai Inc. $720.00 01/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244558888